Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 17, 2026 · 10-Q · 48 days after period end · 0001493152-26-007052
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$3.09M | -$430.18K | -$584.38K | -$485.42K |
| EPS Diluted | -$0.30 | -$32.23 | -$1,559.55 | -$0.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end
